14.90
-0.26(-1.72%)
Currency In USD
| Previous Close | 15.16 |
| Open | 15.12 |
| Day High | 15.34 |
| Day Low | 14.8 |
| 52-Week High | 16.2 |
| 52-Week Low | 6.99 |
| Volume | 467,664 |
| Average Volume | 2.25M |
| Market Cap | 1.77B |
| PE | -12.84 |
| EPS | -1.16 |
| Moving Average 50 Days | 13.55 |
| Moving Average 200 Days | 10.9 |
| Change | -0.26 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $683.49 as of March 13, 2025 at a share price of $14.9. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 3 years ago, it would be worth $946.63 as of March 13, 2025 at a share price of $14.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
GlobeNewswire Inc.
Mar 07, 2025 1:00 PM GMT
Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) with prior inadequate response, intolerance, and contraindications to topical treatmentsNew patient repo
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
GlobeNewswire Inc.
Feb 28, 2025 2:00 PM GMT
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical treatments including topical steroidsSecond poste
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
GlobeNewswire Inc.
Feb 26, 2025 1:00 PM GMT
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025 Application supported by positive efficacy and safety data from pivotal Phase 3 trial, pivotal long-term extension study,